GSK unveils innovative products at second China International Import Expo

Gathering global medical innovation to help build a healthy China

Pharmaceutical giant GlaxoSmithKline said it is determined to resonate with China's unremitting pursuit for healthier livelihoods, as it debuted its latest range of innovative products and solutions at the second China International Import Expo starting on Tuesday.

The solutions related to respiratory diseases, vaccines, hepatitis, HIV/AIDS, immunology diseases, among others, and represent a strong commitment to bringing innovation and partnership to China.

"It is incredible to observe – and at GSK to be part of – the rapid progress the Chinese government has made in healthcare and the measurable impact this has had for people in China," said Emma Walmsley, chief executive officer of GSK said during the booth opening ceremony.

"We believe GSK can play an important role in this transformation. Our focus is very much aligned with government's goal in bringing innovation and partnership in respiratory diseases, vaccines and specialty care."

Working on innovation, benefiting Chinese patients with global innovations

GSK was one of the first multinational pharmaceutical companies to enter the China market. As a science-led global healthcare company, GSK has devoted itself to bringing global leading innovative products into China with its strong R&D strength. Since 2010, GSK has registered 19 medicines in China, and it will continue to bring more innovative medicines and vaccines to the market, the company said.

It will also optimize its plan for launching new products in China and increase its movement in meeting increasing healthcare needs, contributing to the government's vision of "Healthy China 2030".

At the CIIE, GSK's booth, covering up to 600 square meters, has a full display of achievements in innovative development, local investment and cooperative programs. A wide range of innovative medicines, vaccines and medical solutions made their Chinese debut at the expo.

More efforts for co-development with China's pharmaceutical industry

GSK keeps investing in China, accelerating the connection between China's pharmaceutical industry with the rest of the world, empowering China's local pharmaceutical industry in terms of innovation and development, demonstrating GSK's commitment to being partners in China, with China and for China.

GSK and Innovax, a wholly-owned subsidiary of Beijing Wantai Biological Pharmaceutical, under the YangShengTang Group, signed a global cooperative agreement in with GSK in September, aiming to co-develop a new generation of HPV vaccine based on innovative antigen technologies from Xiamen University and GSK's Adjuvant System. The cooperation will help speed up the research and development of an HPV vaccine and improve access.

Working together to build China's ecosystem for disease control and prevention

Supporting China's "Internet + Healthcare" strategy, GSK, together with its industrial partners, is also working actively on building China's first digital ecological management system for chronic obstructive pulmonary disease, through internet technologies and a smart diagnosis and treatment model.

In order to improve its ability in preventing and treating major diseases at the grassroots level in China, GSK has joined forces with China Primary Health Care Foundation to launch China's first SLE patient assistance program, aiming to offer innovative drugs required for regulated treatment to SLE patients who meet eligibility requirements for assistance.

"The presence of GSK in this year's import expo marks a special milestone in our commitment to help people of China do more, feel better, live longer," said Fabio Landazabal, senior vice-president of GSK Emerging Markets.

"The theme of this years' expo "New Era, Shared Future" describes perfectly the moment GSK is embarking on -- to be the most innovative, best performing and trusted healthcare company in China."